(19)
(11) EP 2 758 419 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.04.2017 Bulletin 2017/16

(45) Mention of the grant of the patent:
19.10.2016 Bulletin 2016/42

(21) Application number: 12766825.9

(22) Date of filing: 20.09.2012
(51) International Patent Classification (IPC): 
C07J 63/00(2006.01)
A61P 31/18(2006.01)
 A61K 31/56(2006.01)
(86) International application number:
PCT/US2012/056186
(87) International publication number:
WO 2013/043778 (28.03.2013 Gazette 2013/13)

(54)

NOVEL BETULINIC ACID DERIVATIVES WITH ANTIVIRAL ACTIVITY

NEUE BETULINSÄUREDERIVATE MIT ANTIVIRALER WIRKUNG

NOUVEAUX DÉRIVÉS D'ACIDE BÉTULINIQUE AYANT UNE ACTIVITÉ ANTIVIRALE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 21.09.2011 US 201161537099 P

(43) Date of publication of application:
30.07.2014 Bulletin 2014/31

(73) Proprietor: VIIV Healthcare UK (No.5) Limited
Brentford, Middlesex TW8 9GS (GB)

(72) Inventors:
  • LIU, Zheng
    Wallingford, CT 06492 (US)
  • MEANWELL, Nicholas A.
    Wallingford, CT 06492 (US)
  • REGUEIRO-REN, Alicia
    Wallingford, CT 06492 (US)

(74) Representative: Learoyd, Stephanie Anne 
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-2009/100532
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).